Neuronetics, Inc.: peers
Neuronetics, Inc. beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.
Side by side#
Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.
| Measure | Neuronetics, Inc.base STIM · 🇺🇸 US Percentile in Healthcare Percentile in USA | MaxCyte, Inc. MXCT · 🇺🇸 US Percentile in Healthcare Percentile in USA | Exagen Inc. XGN · 🇺🇸 US Percentile in Healthcare Percentile in USA | Anixa Biosciences, Inc. ANIX · 🇺🇸 US Percentile in Healthcare Percentile in USA | Biodesix, Inc. BDSX · 🇺🇸 US Percentile in Healthcare Percentile in USA | Insight Molecular Diagnostics Inc. IMDX · 🇺🇸 US Percentile in Healthcare Percentile in USA | Sera Prognostics, Inc. SERA · 🇺🇸 US Percentile in Healthcare Percentile in USA | NRC Health NRC · 🇺🇸 US Percentile in Healthcare Percentile in USA | Group median |
|---|---|---|---|---|---|---|---|---|---|
| Size | |||||||||
| Market cap (Better neither way: ranked highest first) | $162 MOct 23, 2026 · Market data4th of 8 | $156 MOct 27, 2026 · Market data5th of 8 | $218 MOct 16, 2026 · Market data3rd of 8 | $117 MOct 29, 2026 · Market data6th of 8 | $265 MOct 23, 2026 · Market data2nd of 8 | $98 MOct 27, 2026 · Market data7th of 8 | $82 MOct 30, 2026 · Market data8th of 8 | $465 MOct 26, 2026 · Market data1st of 8 | $159 M8 ranked |
| Revenue (Better neither way: ranked highest first) | $149 MFY2025 · SEC1st of 7 | $33 MFY2025 · SEC5th of 7 | $67 MFY2025 · SEC4th of 7 | —— | $89 MFY2025 · SEC3rd of 7 | $4 MFY2025 · SEC6th of 7 | $0 MFY2025 · SEC7th of 7 | $137 MFY2025 · SEC2nd of 7 | $67 M7 ranked |
| Net income (Higher is better) | $-39 MFY2025 · SEC6th of 8 | $-45 MFY2025 · SEC7th of 8 | $-20 MFY2025 · SEC3rd of 8 | $-11 MFY2025 · SEC2nd of 8 | $-35 MFY2025 · SEC5th of 8 | $-50 MFY2025 · SEC8th of 8 | $-32 MFY2025 · SEC4th of 8 | $12 MFY2025 · SEC1st of 8 | $-34 M8 ranked |
| Employees (Better neither way: ranked highest first) | —— | 91December 31, 2025 · Profile3rd of 4 | 220December 31, 2025 · Profile2nd of 4 | —— | —— | —— | 72December 31, 2025 · Profile4th of 4 | 357December 31, 2025 · Profile1st of 4 | 1564 ranked |
| Growth | |||||||||
| Market cap change, 30 days (Higher is better) | -27.8%30 days to Oct 23, 2026 · Market data2nd of 2 | —— | +1.8%30 days to Oct 16, 2026 · Market data1st of 2 | —— | —— | —— | —— | —— | -13.0%2 ranked |
| Revenue growth (Higher is better) | +99.2%FY2025 · SEC2nd of 691st96th | -14.5%FY2025 · SEC6th of 612th8th | +19.7%FY2025 · SEC4th of 667th78th | ———— | +24.1%FY2025 · SEC3rd of 673rd82nd | +116.0%FY2025 · SEC1st of 693rd97th | ———— | -4.0%FY2025 · SEC5th of 618th19th | +21.9%6 ranked |
| Revenue growth, 3 years a year (Higher is better) | +31.8%FY2025 · SEC3rd of 682nd92nd | -9.3%FY2025 · SEC6th of 612th11th | +13.5%FY2025 · SEC4th of 661st77th | ———— | +32.3%FY2025 · SEC2nd of 683rd92nd | +61.7%FY2025 · SEC1st of 692nd97th | ———— | -3.2%FY2025 · SEC5th of 619th23rd | +22.6%6 ranked |
| Margins and returns | |||||||||
| Gross margin (Higher is better) | 48.5%FY2025 · SEC4th of 434th61st | 81.1%FY2025 · SEC1st of 482nd92nd | 58.3%FY2025 · SEC2nd of 449th72nd | ———— | ———— | 56.6%FY2025 · SEC3rd of 448th70th | ———— | ———— | 57.5%4 ranked |
| Operating margin (Higher is better) | -21.1%FY2025 · SEC2nd of 541st21st | -157.1%FY2025 · SEC5th of 518th7th | -21.1%FY2025 · SEC3rd of 540th21st | ———— | -31.5%FY2025 · SEC4th of 538th18th | ———— | ———— | 16.4%FY2025 · SEC1st of 584th80th | -21.1%5 ranked |
| Net margin (Higher is better) | -26.1%FY2025 · SEC2nd of 541st20th | -135.1%FY2025 · SEC5th of 520th8th | -30.0%FY2025 · SEC3rd of 538th18th | ———— | -39.8%FY2025 · SEC4th of 534th16th | ———— | ———— | 8.4%FY2025 · SEC1st of 576th71st | -30.0%5 ranked |
| Free cash flow margin (Higher is better) | -14.2%FY2025 · SEC2nd of 640th19th | -109.5%FY2025 · SEC5th of 620th7th | -21.4%FY2025 · SEC3rd of 636th16th | ———— | -26.6%FY2025 · SEC4th of 634th15th | -624.6%FY2025 · SEC6th of 64th1st | ———— | 11.5%FY2025 · SEC1st of 675th73rd | -24.0%6 ranked |
| Return on equity (Higher is better) | -155.7%FY2025 · SEC6th of 615th7th | -23.6%FY2025 · SEC2nd of 659th26th | -147.8%FY2025 · SEC5th of 616th7th | -62.2%FY2025 · SEC4th of 637th16th | ———— | ———— | -51.8%FY2025 · SEC3rd of 642nd18th | 51.3%FY2025 · SEC1st of 697th96th | -57.0%6 ranked |
| Return on invested capital (Higher is better) | ———— | ———— | ———— | ———— | ———— | ———— | ———— | 17.3%FY2025 · SEConly one with it72nd72nd | 17.3%— |
| Valuation | |||||||||
| P/E ratio (Better neither way: ranked highest first) | ———— | ———— | ———— | ———— | ———— | ———— | ———— | 72.3×price Oct 26, 2026 · Market dataonly one with it82nd92nd | 72.3×— |
| Price to sales (Better neither way: ranked highest first) | 1.0×price Oct 23, 2026 · Market data6th of 617th29th | 4.5×price Oct 27, 2026 · Market data2nd of 655th74th | 3.0×price Oct 16, 2026 · Market data4th of 644th61st | ———— | 2.5×price Oct 23, 2026 · Market data5th of 639th55th | 24.2×price Oct 27, 2026 · Market data1st of 685th95th | ———— | 3.2×price Oct 26, 2026 · Market data3rd of 645th63rd | 3.1×6 ranked |
| Price to book (Better neither way: ranked highest first) | 7.2×price Oct 23, 2026 · Market data4th of 678th84th | 0.9×price Oct 27, 2026 · Market data6th of 617th18th | 12.5×price Oct 16, 2026 · Market data2nd of 687th92nd | 7.7×price Oct 29, 2026 · Market data3rd of 679th85th | ———— | ———— | 1.1×price Oct 30, 2026 · Market data5th of 620th23rd | 33.3×price Oct 26, 2026 · Market data1st of 695th97th | 7.5×6 ranked |
| Free cash flow yield (Higher is better) | -13.1%price Oct 23, 2026 · Market data5th of 839th18th | -23.2%price Oct 27, 2026 · Market data6th of 830th13th | -6.5%price Oct 16, 2026 · Market data3rd of 850th25th | -5.3%price Oct 29, 2026 · Market data2nd of 854th27th | -8.9%price Oct 23, 2026 · Market data4th of 845th22nd | -25.8%price Oct 27, 2026 · Market data7th of 828th13th | -32.2%price Oct 30, 2026 · Market data8th of 826th11th | 3.4%price Oct 26, 2026 · Market data1st of 880th56th | -11.0%8 ranked |
| Financial strength | |||||||||
| Debt to equity (Lower is better) | 2.9×FY2025 · SEC2nd of 392nd90th | ———— | 1.3×FY2025 · SEC1st of 381st76th | ———— | ———— | ———— | ———— | 5.4×FY2025 · SEC3rd of 395th95th | 2.9×3 ranked |
| Net debt to EBITDA (Lower is better) | ———— | ———— | ———— | ———— | ———— | ———— | ———— | 2.4×FY2025 · SEConly one with it59th54th | 2.4×— |
| Interest cover (Higher is better) | -4.1×FY2025 · SEC2nd of 258th33rd | ———— | ———— | ———— | -3.6×FY2025 · SEC1st of 260th34th | ———— | ———— | ———— | -3.9×2 ranked |
| Piotroski F-score (Higher is better) | 4 of 9FY2025 · SEC1st of 2 | —— | 3 of 9FY2025 · SEC2nd of 2 | —— | —— | —— | —— | —— | 3.5 of 92 ranked |
| Scorecard | |||||||||
| Scorecard (Higher is better) | 7 of 22FY2025 · Scorecard4th of 8 | 3 of 20FY2025 · Scorecard7th of 8 | 8 of 22FY2025 · Scorecard3rd of 8 | 2 of 12FY2025 · Scorecard6th of 8 | 8 of 20FY2025 · Scorecard2nd of 8 | 5 of 17FY2025 · Scorecard5th of 8 | 2 of 14FY2025 · Scorecard8th of 8 | 13 of 29FY2025 · Scorecard1st of 8 | 31% passed8 ranked |
| Valuation checks (Higher is better) | 1 of 5FY2025 · Scorecard2nd of 8 | 1 of 5FY2025 · Scorecard2nd of 8 | 1 of 5FY2025 · Scorecard2nd of 8 | 0 of 4FY2025 · Scorecard7th of 8 | 1 of 5FY2025 · Scorecard2nd of 8 | 0 of 5FY2025 · Scorecard7th of 8 | 1 of 4FY2025 · Scorecard1st of 8 | 1 of 6FY2025 · Scorecard6th of 8 | 20% passed8 ranked |
| Growth checks (Higher is better) | 4 of 6FY2025 · Scorecard2nd of 8 | 0 of 6FY2025 · Scorecard6th of 8 | 4 of 6FY2025 · Scorecard2nd of 8 | 0 of 2FY2025 · Scorecard6th of 8 | 5 of 6FY2025 · Scorecard1st of 8 | 4 of 6FY2025 · Scorecard2nd of 8 | 0 of 3FY2025 · Scorecard6th of 8 | 1 of 6FY2025 · Scorecard5th of 8 | 42% passed8 ranked |
| Profitability checks (Higher is better) | 1 of 5FY2025 · Scorecard3rd of 8 | 0 of 5FY2025 · Scorecard5th of 8 | 1 of 5FY2025 · Scorecard3rd of 8 | 0 of 3FY2025 · Scorecard5th of 8 | 1 of 4FY2025 · Scorecard2nd of 8 | 0 of 2FY2025 · Scorecard5th of 8 | 0 of 3FY2025 · Scorecard5th of 8 | 5 of 6FY2025 · Scorecard1st of 8 | 10% passed8 ranked |
| Financial health checks (Higher is better) | 1 of 5FY2025 · Scorecard8th of 8 | 1 of 3FY2025 · Scorecard4th of 8 | 2 of 5FY2025 · Scorecard3rd of 8 | 1 of 2FY2025 · Scorecard2nd of 8 | 1 of 4FY2025 · Scorecard7th of 8 | 1 of 3FY2025 · Scorecard4th of 8 | 1 of 3FY2025 · Scorecard4th of 8 | 3 of 5FY2025 · Scorecard1st of 8 | 33% passed8 ranked |
| Shareholder returns checks (Higher is better) | 0 of 1FY2025 · Scorecard4th of 8 | 1 of 1FY2025 · Scorecard1st of 8 | 0 of 1FY2025 · Scorecard4th of 8 | 1 of 1FY2025 · Scorecard1st of 8 | 0 of 1FY2025 · Scorecard4th of 8 | 0 of 1FY2025 · Scorecard4th of 8 | 0 of 1FY2025 · Scorecard4th of 8 | 3 of 6FY2025 · Scorecard3rd of 8 | 0% passed8 ranked |
| Ownership | |||||||||
| Held by institutions (Better neither way: ranked highest first) | 57.9%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 8 | 62.8%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 8 | 40.9%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in7th of 8 | 18.4%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in8th of 8 | 41.3%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 8 | 56.7%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 8 | 49.0%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 8 | 51.2%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 8 | 50.1%8 ranked |
| Institutions holding (Better neither way: ranked highest first) | 962026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 8 | 1192026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 8 | 782026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 8 | 752026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 8 | 602026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 8 | 442026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in8th of 8 | 482026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in7th of 8 | 1262026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 8 | 778 ranked |
| Institutional holding, change over the quarter (Better neither way: ranked highest first) | -11.3 pp2026-Q2 against 2026-Q1 · 13F7th of 7 | +0.3 pp2026-Q2 against 2026-Q1 · 13F4th of 7 | -6.1 pp2026-Q2 against 2026-Q1 · 13F6th of 7 | +0.5 pp2026-Q2 against 2026-Q1 · 13F2nd of 7 | +2.2 pp2026-Q2 against 2026-Q1 · 13F1st of 7 | -2.5 pp2026-Q2 against 2026-Q1 · 13F5th of 7 | —— | +0.5 pp2026-Q2 against 2026-Q1 · 13F3rd of 7 | +0.3 pp7 ranked |
| Dividends | |||||||||
| Dividend yield (Higher is better) | ———— | ———— | ———— | ———— | ———— | ———— | ———— | 2.4%FY2025 · SEConly one with it82nd55th | 2.4%— |
| Shareholder yield (Higher is better) | ———— | ———— | ———— | ———— | ———— | ———— | ———— | 6.7%FY2025 · SEConly one with it82nd78th | 6.7%— |
| Dividend payout (Better neither way: ranked highest first) | ———— | ———— | ———— | ———— | ———— | ———— | ———— | 94.7%FY2025 · SEConly one with it92nd82nd | 94.7%— |
| Dividend per share (Better neither way: ranked highest first) | —— | —— | —— | —— | —— | —— | —— | $0.52FY2025 · SEConly one with it | $0.52— |
Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).
Key: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = Neuronetics, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; MaxCyte, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Exagen Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Anixa Biosciences, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Biodesix, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Insight Molecular Diagnostics Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Sera Prognostics, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; NRC Health: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover.
Where each stands in its sector and country: Operating margin#
The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.
| Company | Operating margin | In its sector | In its country |
|---|---|---|---|
| Neuronetics, Inc. | -21.1%FY2025 | 41st percentile in Healthcaremedian -7.8%, 678 companies | 21st percentile in USAmedian 3.4%, 2,607 companies |
| MaxCyte, Inc. | -157.1%FY2025 | 18th percentile in Healthcaremedian -7.8%, 678 companies | 7th percentile in USAmedian 3.4%, 2,607 companies |
| Exagen Inc. | -21.1%FY2025 | 40th percentile in Healthcaremedian -7.8%, 678 companies | 21st percentile in USAmedian 3.4%, 2,607 companies |
| Anixa Biosciences, Inc. | — | — | — |
| Biodesix, Inc. | -31.5%FY2025 | 38th percentile in Healthcaremedian -7.8%, 678 companies | 18th percentile in USAmedian 3.4%, 2,607 companies |
| Insight Molecular Diagnostics Inc. | — | — | — |
| Sera Prognostics, Inc. | — | — | — |
| NRC Health | 16.4%FY2025 | 84th percentile in Healthcaremedian -7.8%, 678 companies | 80th percentile in USAmedian 3.4%, 2,607 companies |
Revenue by fiscal year, and the rank in the group#
Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).
Revenue
Rank in the group
| Fiscal year | Neuronetics, Inc. | MaxCyte, Inc. | Exagen Inc. | Anixa Biosciences, Inc. | Biodesix, Inc. | Insight Molecular Diagnostics Inc. | Sera Prognostics, Inc. | NRC Health |
|---|---|---|---|---|---|---|---|---|
| 2025 | $149 MSEC1st | $33 MSEC5th | $67 MSEC4th | — | $89 MSEC3rd | $4 MSEC6th | $0 MSEC7th | $137 MSEC2nd |
| 2024 | $75 MSEC2nd | $39 MSEC5th | $56 MSEC4th | $0 MSEC7th | $71 MSEC3rd | $2 MSEC6th | $0 MSEC8th | $143 MSEC1st |
| 2023 | $71 MSEC2nd | $41 MSEC5th | $53 MSEC3rd | $0 MSEC8th | $49 MSEC4th | $2 MSEC6th | $0 MSEC7th | $149 MSEC1st |
| 2022 | $65 MSEC2nd | $44 MSEC4th | $46 MSEC3rd | — | $38 MSEC5th | $1 MSEC6th | $0 MSEC7th | $152 MSEC1st |
| 2021 | $55 MSEC2nd | $34 MSEC5th | $48 MSEC4th | $1 MSEC7th | $55 MSEC3rd | $2 MSEC6th | $0 MSEC8th | $148 MSEC1st |
| 2020 | $49 MSEC2nd | $26 MSEC5th | $42 MSEC4th | — | $46 MSEC3rd | $1 MSEC6th | $0 MSEC7th | $133 MSEC1st |
| 2019 | $63 MSEC2nd | $22 MSEC5th | $40 MSEC3rd | $0 MSEC6th | $25 MSEC4th | — | — | $128 MSEC1st |
| 2018 | $53 MSEC2nd | — | $32 MSEC3rd | $1 MSEC4th | — | — | — | $120 MSEC1st |
| 2017 | $40 MSEC2nd | — | — | $0 MSEC3rd | — | — | — | $118 MSEC1st |
| 2016 | $34 MSEC2nd | — | — | $0 MSEC3rd | — | — | — | $109 MSEC1st |
| 2015 | — | — | — | $9 MSEC2nd | — | — | — | $102 MSEC1st |
| 2014 | — | — | — | $4 MSEC2nd | — | — | — | $99 MSEC1st |
Key: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.
Suggested peers of Neuronetics, Inc.#
Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.
- MaxCyte, Inc.MXCT · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $156 M market cap against $162 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $156 M (Oct 27, 2026) · revenue $33 M (year to December 2025)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- Exagen Inc.XGN · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $218 M market cap against $162 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $218 M (Oct 16, 2026) · revenue $67 M (year to December 2025)98 of 100 (industry or sector 50 + size 28 + country 15 + figures on file 5)In the group
- Anixa Biosciences, Inc.ANIX · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $117 M market cap against $162 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $117 M (Oct 29, 2026)98 of 100 (industry or sector 50 + size 28 + country 15 + figures on file 5)In the group
- Biodesix, Inc.BDSX · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $265 M market cap against $162 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $265 M (Oct 23, 2026) · revenue $89 M (year to December 2025)97 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)In the group
- Insight Molecular Diagnostics Inc.IMDX · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $98 M market cap against $162 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $98 M (Oct 27, 2026) · revenue $4 M (year to December 2025)97 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)In the group
- Sera Prognostics, Inc.SERA · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $82 M market cap against $162 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $82 M (Oct 30, 2026) · revenue $0 M (year to December 2025)96 of 100 (industry or sector 50 + size 26 + country 15 + figures on file 5)In the group
- NRC HealthNRC · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $465 M market cap against $162 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $465 M (Oct 26, 2026) · revenue $137 M (year to December 2025)93 of 100 (industry or sector 50 + size 23 + country 15 + figures on file 5)In the group
- IB Acquisition Corp.IBAC · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $55 M market cap against $162 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $55 M (Sep 28, 2026)93 of 100 (industry or sector 50 + size 23 + country 15 + figures on file 5)+ Add
- Standard BioTools Inc.FLDM · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $243 M market cap against $162 M · Same country: USAMarket cap $243 M (last known, Jan 7, 2022) · revenue $138 M (year to December 2020)92 of 100 (industry or sector 50 + size 27 + country 15)+ Add
- Myriad Genetics, Inc.MYGN · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $531 M market cap against $162 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $531 M (Oct 21, 2026) · revenue $825 M (year to December 2025)92 of 100 (industry or sector 50 + size 22 + country 15 + figures on file 5)+ Add
- Fulgent Genetics, Inc.FLGT · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $582 M market cap against $162 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $582 M (Oct 9, 2026) · revenue $323 M (year to December 2025)92 of 100 (industry or sector 50 + size 22 + country 15 + figures on file 5)+ Add
- DarioHealth Corp.DRIO · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $42 M market cap against $162 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $42 M (Oct 22, 2026) · revenue $22 M (year to December 2025)91 of 100 (industry or sector 50 + size 21 + country 15 + figures on file 5)+ Add
Any figure over the years, other peers or a saved group: open this group in the peer workspace.